Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) EBITDA (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed EBITDA for 4 consecutive years, with -$27.5 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 57.97% to -$27.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$127.8 million, a 41.2% increase, with the full-year FY2025 number at -$127.8 million, up 41.2% from a year prior.
  • EBITDA was -$27.5 million for Q4 2025 at Day One Biopharmaceuticals, down from -$24.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $29.6 million in Q3 2024 to a low of -$114.8 million in Q2 2024.
  • A 4-year average of -$43.6 million and a median of -$41.9 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: skyrocketed 157.61% in 2024, then crashed 181.83% in 2025.
  • Day One Biopharmaceuticals' EBITDA stood at -$42.7 million in 2022, then plummeted by 39.24% to -$59.5 million in 2023, then fell by 9.77% to -$65.3 million in 2024, then skyrocketed by 57.97% to -$27.5 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's EBITDA are -$27.5 million (Q4 2025), -$24.3 million (Q3 2025), and -$35.0 million (Q2 2025).